IPX 6-K

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

FORM 6-K

---

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

Date: March 16, 2026

Commission File Number: 001-41338

---

IperionX Limited

(Translation of registrant’s name into English)

---

1092 Confroy Drive

South Boston, Virginia

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

---

---

EXHIBIT INDEX

The following exhibits are filed as part of this Form 6-K:

Exhibit	Description
99.1	ASX Correspondence

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IPERIONX LIMITED
	(registrant)
Date: March 16, 2026	By:	/s/ Marcela Castro
Name:	Marcela Castro
---	---
Title:	Chief Financial Officer

---

---

Exhibit 99.1

March 16, 2026

ASX Compliance

Level 40 Central Park

152-158 St Georges Terrace

PERTH WA 6000

Response to ASX Price Query

IperionX Limited (NASDAQ: IPX, ASX: IPX) (IperionX) provides this response in relation to ASX’s letter dated 16 March 2026 regarding a change in the price of IPX’s securities from a high of $6.93 on 12 March 2026 to an intraday low of $4.58 today.

In response to the questions detailed in ASX’s letter the Company advises as follows:

1.	Is IPX aware of any information concerning it that has not been announced to the market which, if known by some in the market,<br> could explain the recent trading in its securities?

No.

2.	If the answer to question 1 is “yes”

Not applicable.

3.	If the answer to question 1 is “no”, is there any other explanation that IPX may have for the recent trading in its securities?

The Company is not aware of any reason or information which could be an explanation for the manner of trading in the Company’s securities over the period.

The Company notes that its half year report was released last week, and it has received requests from stakeholders for further information relating to the funding mechanics of its U.S. Department of War grants, provided below:

1.	IperionX makes cash payments for spending upon projects under its U.S. Department of War grants.
2.	The U.S. Government subsequently re-imburses IperionX after these payments have been made.
---	---
3.	For the period to Dec 31, 2025, approximately $6.6 million in payments were incurred that were not yet reimbursed.
---	---
4.	Under IperionX’s accounting treatment, the Company procures equipment solely in an agency capacity on behalf of the U.S. Government. When an asset is<br> purchased for the U.S. Government, IperionX records a receivable representing the amount due for reimbursement, rather than recognizing the asset or related expense.
---	---
5.	The U.S. Government can elect to, but is not obliged to, transfer title to all or a portion of equipment or real property to IperionX at the<br> conclusion of the U.S. Department of War projects.
---	---
6.	As previously disclosed in the December 31, 2025 quarterly activities report, a balance of $46.5 million remains available for reimbursement from the<br> U.S. Government.
---	---
4.	Please confirm that the Entity is in compliance with the Listing Rules and, in particular, Listing Rule 3.1
---	---

The Company confirms that it is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

5.	Approval of responses

The above responses have been authorized and approved by the Managing Director and CEO of IPX with delegated authority from the board to respond to ASX on disclosure matters.

Yours faithfully

IperionX Limited

Louisa Martino

Company Secretary

	Virginia	Tennessee	Utah
1092 Confroy Drive<br><br> <br>South Boston, VA 24592		279 West Main Street<br><br> <br>Camden, TN 38320	1782 W 2300 S<br><br> <br>West Valley City, UT 84119
IperionX Limited ABN 84 618 935 372

---